Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449609 | 0.86 | LMNA (0.52) | SMN1; SMN2LMNAALDH1A1SIGMAR1TAAR1 | |
| Dimethylformamide SCHEMBL8332170 | 0.82 | TAAR1 (0.54) | ALDH1A1SIGMAR1TAAR1KMT2AALOX5 | |
| Dihydrocinnamaldehyde SCHEMBL598211 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAALDH1A1TAAR1KMT2A | |
| Acetone SCHEMBL18600592 | 0.81 | ALDH1A1 (0.48) | SMN1; SMN2LMNAALDH1A1MAPTKMT2A | |
| Dimethylformamide SCHEMBL314310 | 0.80 | LMNA (0.60) | LMNA | |
| Phenylacetaldehyde SCHEMBL452558 | 0.80 | LMNA (0.44) | SMN1; SMN2LMNASIGMAR1TAAR1KMT2A | |
| SCHEMBL585803 | 0.78 | LMNA (0.46) | SMN1; SMN2LMNASIGMAR1L3MBTL1 | |
| Phenylacetaldehyde SCHEMBL1412189 | 0.77 | LMNA (0.41) | SMN1; SMN2LMNASIGMAR1TAAR1KMT2A | |
| Dimethylformamide SCHEMBL131192 | 0.77 | LMNA (0.55) | LMNA | |
| Dimethylformamide SCHEMBL133174 | 0.77 | LMNA (0.55) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| US-5962675-A | Chemical syntheses of 2'-O-methoxy purine nucleosides | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | claimed |
| EP-0886641-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | claimed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | claimed |
| EP-1727803-B3 | PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF | ARENA PHARM INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-1727803-B1 | PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF | ARENA PHARM INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7812176-B2 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7312342-B2 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)-methanone and salts thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-12-25 | — | — | US | disclosed |
| US-20070293685-A1 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1727803-A1 | PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF | Arena Pharmaceuticals, Inc. (US) | 2006-12-06 | — | — | EP | disclosed |
| US-7067689-B1 | Process for production of pentahydroxyhexylcarbamoyl alkanoic acids | MICROBIA, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-0033195-B1 | PYRIMIDINE-2-SULPHIDES AND THEIR S-OXIDES FOR USE IN MEDICINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION AND SUCH COMPOUNDS WHEN NOVEL PER SE | NYEGAARD & CO. A/S (NO) | 1985-12-04 | — | — | EP | disclosed |
| US-4423047-A | INHIBITING ABNORMAL CELL PROLIFERATION | NYEGAARD & CO. A/S (NO) | 1983-12-27 | — | — | US | disclosed |
| EP-0033195-A1 | Pyrimidine-2-sulphides and their S-oxides for use in medicine, pharmaceutical compositions containing them, processes for their preparation and such compounds when novel per se | NYEGAARD & CO. A/S (NO) | 1981-08-05 | — | — | EP | disclosed |
| US-4017313-A | Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-3979410-A | Intermediate α-acyl-β-dialkylamino-2-nitrostyrenes | HOFFMANN-LA ROCHE INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3976639-A | Intermediates for indoles | HOFFMANN-LA ROCHE INC. (US) | 1976-08-24 | — | — | US | disclosed |
| US-3931225-A | Process for preparing o-nitrobenzylketones | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293685-A1 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | HTR5A, HTR2C, HTR2A | ATM 3190/4885SMN1; SMN2 4371/4885LMNA 3513/4885 |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | UMPS, PNP, NUDT1 | ATM 2176/4885SMN1; SMN2 1516/4885LMNA 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.